Research Letter: Open Science

Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?

Results from the KEYNOTE-564 trial were published 1 yr ago in the New England Journal of Medicine [1]. Patients with clear-cell renal cell carcinoma (ccRCC) who met the protocol-defined criteria for high risk of recurrence (stage T2 with nuclear grade 4 or sarcomatoid differentiation, stage T3, regional lymph-node metastasis, or stage M1 with no evidence of disease [NED]) were randomly assigned to receive either adjuvant pembrolizumab or placebo. The primary endpoint was disease-free survival (DFS). Within this pivotal randomized clinical trial, treatment with pembrolizumab showed a disease-free survival (DFS) benefit compared to placebo (DFS at 24 mo: 77.3% vs 68.1%) [1]. Grade ≥3 adverse events occurred in 32.4% of the patients who received pembrolizumab and 17.7% of those who received placebo. In the updated analysis after 30 mo of follow-up, adjuvant pembrolizumab continued to show a benefit in DFS compared with placebo (hazard ratio 0.63, 95% confidence interval 0.50–0.80) [2] both in the intention-to-treat population and across several prespecified and exploratory subgroups. Subgroup analyses showed a benefit irrespective of the presence of sarcomatoid features, nuclear tumor grade 4, or M1 with NED status at baseline, although the numbers in some subgroups were small and should be interpreted with caution [2]. The safety profile of adjuvant pembrolizumab remained consistent with the primary findings of the study [1]. However, overall survival (OS) data are still immature.

In this scenario, both the European Association of Urology and European Society of Medical Oncology changed their guidelines, introducing a (weak) recommendation for adjuvant pembrolizumab following surgery with curative intent in patients with ccRCC meeting the KEYNOTE-564 study criteria [3,4]. Accordingly, the European Medicines Agency approved the use of pembrolizumab as monotherapy in the adjuvant setting [5].

Notably, several issues regarding patient selection and the cost-effectiveness of adjuvant immunotherapy need to be addressed.

First, while patient selection is key, achieving this goal in clinical practice is still an unmet need. Namely, understanding how to pick the right patients from eligible candidates (for whom the risk of treatment-related harm may be worth the benefit) is complex and nuanced.

From an oncological standpoint, patients with non-metastatic ccRCC who might be offered adjuvant immunotherapy may harbor heterogeneous disease entities that cannot be captured by the KEYNOTE-564 criteria [1]. According to the Leibovich score [6] and the ECOG-ACRIN 2805 (ASSURE) prognostic model [7], the estimated 5-yr DFS varies significantly in each KEYNOTE-564 risk group (Table 1). While these models are not devoid of limitations [6,7], specific prognostic factors (eg, tumor size, World Health Organization/International Society of Urological Pathology grade, presence of necrosis, and vascular invasion, integrated into the above-mentioned scores) might play a key role in modulating the risk of recurrence in individual patients. Overall, the estimated 5-yr DFS among eligible patients may range from 12% to 95% according to the Leibovich score [6] and from 8% to 79% according to the ASSURE model [7]. Therefore, although DFS might not necessarily be a reliable surrogate metric for OS [8], we might argue that the higher the risk of recurrence, the better is the cost/benefit ratio for adjuvant pembrolizumab.

Interestingly, in our prospectively collected multicenter data set (n = 681 consecutive patients with M0 ccRCC treated between 2015 and 2021 at Careggi Hospital, San Luigi Hospital, and UZ Leuven), 26% of the patients could have met the KEYNOTE-564 eligibility criteria, most of whom (87%) had pT3a N0 stage. While these patients would have been classified as “intermediate-high” risk, their estimated 5-yr DFS could range significantly (Table 1), underlying the need to better stratify “eligible” patients using available prognostic models [3,4].

A second issue concerns the potential value of lymph node dissection (LND) in the new era of adjuvant immunotherapy. While patients with pN+ disease represent ideal candidates for adjuvant pembrolizumab [9] (with an estimated 5-yr DFS ranging from 8% to 56% according to the ASSURE model [7]; Table 1), in our data set only 6% of eligible patients had pN+ disease (of whom almost all had pT3–4 ccRCC). This finding highlights the current controversies regarding the anatomical templates and potential benefits of LND for RCC [10]. In fact, current guidelines recommend removal of “clinically enlarged lymph nodes for staging, prognosis and follow-up implications”, and not to offer extended LND to patients with organ-confined disease [3]. However, in patients with cN0 locally advanced disease, pN status might be key in stratifying those at higher risk of relapse after surgery (Table 1) and could refine decision-making.

https://doi.org/10.1016/j.euros.2022.10.002
0302-2838/© 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
| pT stage | pN stage | Grade | KN-564 Risk Group [1] | Leibovich Score (Range) | Estimated 5-yr MFS according to the Leibovich score [6] | Range of Leibovich Risk Groups (Estimated by MFS) | DFS Points [7] (Range) | 5-yr estimated DFS according to DFS Points model (online calculator)* | Range of Risk Groups (5-yr estimated DFS) |
|----------|----------|-------|-----------------------|-----------------------|--------------------------------------------------|-----------------------------------------------|-----------------------|--------------------------------------------------------------------------------|--------------------------------------|
| T1a      | N<sub>0</sub> | Ang    | HIGH-RISK             | 2 to 6                | 40% to 95%                                         | LOW to HIGH (31% to 74%)                       | 7.5 to 11                          | 25% to 56                                                                           | INT to HIGH (33% to 61%)            |
| T1b      | N<sub>1</sub> | Ang    | HIGH-RISK             | 4 to 8                | 12% to 75%                                         | INT to HIGH (31% to 74%)                       | 7.5 to 11                          | 25% to 56                                                                           | INT to HIGH (33% to 61%)            |
| T2a      | N<sub>0</sub> | G1-G2  | INT-HIGH RISK         | 6 to 7                | 12% to 40%                                         | HIGH (31%)                                     | 8.0 to 9.5                         | 37% to 52                                                                           | INT to HIGH (33% to 61%)            |
| T2b      | N<sub>0</sub> | G1-G2  | INT-HIGH RISK         | 7 to 8                | 12% to 32%                                         | HIGH (31%)                                     | 9.0 to 10.5                        | 29% to 45                                                                           | HIGH (33%)                          |
| T2c      | N<sub>1</sub> | Ang    | HIGH-RISK             | 4 to 10               | 12% to 60%                                         | HIGH (31%)                                     | 12 to 13.5                        | 12% to 37                                                                           | HIGH (33%)                          |
| T3a      | N<sub>0</sub> | G1-G2  | INT-HIGH RISK         | 4 to 6                | 40% to 75%                                         | INT to HIGH (31% to 74%)                       | 5.5 to 9.5                         | without vascular invasion: 40% to 79%                                             | LOW to HIGH (33% to 83%)            |
| T3b      | N<sub>0</sub> | G3     | HIGH-RISK             | 5 to 7                | 31% to 65%                                         | HIGH (31%)                                     | 5.5 to 9.5                         | without vascular invasion: 29% to 40%                                             | LOW to HIGH (33% to 83%)            |
| T3c      | N<sub>0</sub> | G4     | HIGH-RISK             | 7 to 9                | 12% to 31%                                         | HIGH (31%)                                     | 8.0 to 12.5                        | without vascular invasion: 31% to 50%                                             | HIGH (33%)                          |
| T4a      | N<sub>0</sub> | G1-G2  | INT-HIGH RISK         | 6 to 8                | 12% to 40%                                         | HIGH (31%)                                     | 8.0 to 12.5                        | without vascular invasion: 12% to 30%                                             | HIGH (33%)                          |
| T4b      | N<sub>0</sub> | G3     | HIGH-RISK             | 9 to 11               | 12% to 31%                                         | HIGH (31%)                                     | 10.5 to 14.5                       | without vascular invasion: 12% to 30%                                             | HIGH (33%)                          |
| T4c      | N<sub>0</sub> | G4     | HIGH-RISK             | 6 to 6                | 40% to 75%                                         | INT to HIGH (31% to 74%)                       | 5.5 to 9.5                         | without vascular invasion: 40% to 79%                                             | LOW to HIGH (33% to 83%)            |
| T5a      | N<sub>0</sub> | G1-G2  | INT-HIGH RISK         | 5 to 7                | 12% to 31%                                         | HIGH (31%)                                     | 8.0 to 12.5                        | without vascular invasion: 29% to 40%                                             | HIGH (33%)                          |
| T5b      | N<sub>0</sub> | G3     | HIGH-RISK             | 6 to 9                | 12% to 31%                                         | HIGH (31%)                                     | 8.0 to 12.5                        | without vascular invasion: 12% to 30%                                             | HIGH (33%)                          |
| T5c      | N<sub>0</sub> | G4     | HIGH-RISK             | 7 to 11               | 12% to 31%                                         | HIGH (31%)                                     | 10.5 to 14.5                       | without vascular invasion: 12% to 30%                                             | HIGH (33%)                          |
| T6a      | N<sub>0</sub> | G1-G2  | HIGH-RISK             | 6 to 6                | 40% to 75%                                         | INT to HIGH (31% to 74%)                       | 4.5 to 9.5                         | without vascular invasion: 40% to 79%                                             | LOW to HIGH (33% to 83%)            |

aPembro = adjuvant pembrolizumab; cRCC = clear - cell renal cell carcinoma; DFS = disease - free survival; HiR = high risk; IR = intermediate risk; KN - 564 KEYNOTE - 564 study; LR = low risk; LS = Leibovich score; MFS = metastasis - free survival VI = va scular invasion.

* Using the online calculator at https://cancernomograms.com/nomograms/492.
Third, the differential impact of adjuvant immunotherapy on DFS and OS across patient populations (M0 vs M1 NED) is still a matter of debate [4]. In the KEYNOTE-564 trial, M1 NED status was defined as complete resection of all metastases at the time of or within 1 yr after nephrectomy [1]. Notably, patients with oligometastatic RCC represent a heterogeneous cohort that requires a multidisciplinary approach. In this context, the potential value of (cytoreductive) nephrectomy plus complete metastasectomy followed by adjuvant pembrolizumab versus upfront PD-1-based combination therapy requires further investigation [3,4].

Lastly, as a non-negligible proportion of patients with ccRCC could meet the KEYNOTE-564 eligibility criteria, the cost-effectiveness and economic sustainability of adjuvant immunotherapy must be carefully assessed, especially in single-payer health care systems.

A recent study using a decision analytic Markov model found that adjuvant pembrolizumab was not cost-effective at a 5-yr time horizon. In fact, at current prices, pembrolizumab was found to be cost-effective only for the subset of ccRCC patients highest risk 5 yr after treatment (including patients with complete metastasectomy, regional lymph node involvement, or pT3 tumors >7 cm with sarcomatoid features) [11].

Given the increasing costs of managing cancer as new agents become available [12] and the current lack of predictive biomarkers, further research is needed to refine patient selection for adjuvant immunotherapy, taking into consideration a variety of factors including granular tumor features (modulating the risk of recurrence; Table 1), the expected survival benefit, treatment-related toxicity, and patients’ life expectancy, quality of life, and preferences.

The applicability of the KEYNOTE-564 findings in real-life scenarios should also be investigated before recommending adjuvant pembrolizumab for all-comers [13].

In summary, despite the positive findings from the KEYNOTE-564 trial [1,2], several unmet clinical needs remain. Furthermore, results from other three adjuvant immune checkpoint inhibitor trials (IMmotion010 [14], PROSPER [15], and CheckMate-914 [16]) have recently been reported. Unfortunately, none of these trials met their primary end-point (improvement in DFS in comparison to placebo or observation), calling again into question the benefits of adjuvant therapy in the field of RCC. Although the explanation for such contradictory results is complex and is likely to be multifactorial, further steps are needed to optimize patient selection (using clinical and molecular biomarkers) and improve the value proposition of adjuvant pembrolizumab for ccRCC at high risk of recurrence.

While we await robust OS data from the KEYNOTE-564 trial, as well as results from the multiarm, multistage RAMPART trial [17] and the LITESPARK-022 trial [18], individualized shared decision-making will be key to reducing the risk of overtreatment by selecting those patients who are most likely to benefit from adjuvant immunotherapy.

Conflicts of interest: The authors have nothing to disclose.

References

[1] Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 2021;385:683–94. https://doi.org/10.1056/NEJMoa2106391.

[2] Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23:1133–44. https://doi.org/10.1016/S1470-2045(22)00487-9.

[3] Bedke J, Albiges L, Capitanio U, et al. 2021 updated European Association of Urology guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma. Eur Urol 2022;81:134–7. https://doi.org/10.1016/j.eururo.2021.11.022.

[4] Powles T, Albiges L, Bex A, et al. ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol 2021;32:1511–9. https://doi.org/10.1093/annonc/mdab177.

[5] European Medicines Agency. CHMP post-authorisation summary of positive opinion for Keytruda (II-108). https://www.ema.europa.eu/en/documents/variations/variation/keytruda-c-003820-ii-0108-epar-assessment-report-variation-en.pdf.

[6] Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:1663–71. https://doi.org/10.1002/cncr.11234.

[7] Correa AF, Jegede FA, Haus NR, et al. Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma. Eur Urol 2021;80:20–31. https://doi.org/10.1016/j.eururo.2021.02.025.

[8] Harshman LC, Xie W, Moreira RB, et al. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: a trial-level meta-analysis. Cancer 2018;124:925–33. https://doi.org/10.1002/cncr.31154.

[9] Capitanio U, Larcher A, Montorsi F, Re: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 2021;385:94: Adjuvant pembrolizumab after nephrectomy: a plea to reconsider the need for lymph node dissection. Eur Urol 2022;81:94. https://doi.org/10.1016/j.eururo.2021.05.034.

[10] Bhindi B, Wallis CJ, Boorjian SA, et al. The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. BJU Int 2018;121:684–98. https://doi.org/10.1111/bju.14127.

[11] Sharma V, Wymer KM, Joyce DD, et al. Cost effectiveness of adjuvant pembrolizumab after nephrectomy for high risk renal cell carcinoma: insights for patient selection from a Markov model. J Urol. In press. https://doi.org/10.1097/JU.0000000000002953.

[12] Martini A, Mottet N, Montorsi F, et al. A plea for economically sustainable evidence-based guidelines. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.001.

[13] Pall G, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2022;400:1103–16. https://doi.org/10.1016/S0140-6736(22)01658-0.

[14] Allaf M, Kim SE, Harshman LC, et al. LBA67 – Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EAR143), a National Clinical Trials Network trial. Ann Oncol 2022;33:S1432–3. https://doi.org/10.1093/annonc/mdac2022.08.072.

[15] Motzer RJ, Russo P, Gruenwald V, et al. LBA4 – Adjuvant nivolumab plus ipilimumab (NIVO+IP) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: results from the randomized, phase III CheckMate 914 trial. Ann Oncol 2022;33:S1430. https://doi.org/10.1093/annonc/mdac2022.08.069.

[16] Oza B, Frangou E, Smith B, et al. RAMPART: a phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemp Clin Trials 2021;108:106482. https://doi.org/10.1016/j.cct.2021.106482.

[17] Choueiri TK, Bedke J, Karam JA, et al. LITESPARK-022: a phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC). J Clin Oncol 2022;40:TPS4602. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS4602.
Riccardo Campi a,b,* on behalf of the European Association of Urology Young Academic Urologists Renal Cancer Working Group

a European Association of Urology Young Academic Urologists Renal Cancer Working Group, Arnhem, The Netherlands

b Department of Urology, SS Annunziata Hospital, G. D’Annunzio University of Chieti, Chieti, Italy

c Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy

d Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy

e Department of Urology, University Hospital Henri Mondor, APHP, Créteil, France

f Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands

g Urology Clinic, Department of Medical, Surgical and Health Science, University of Trieste, Trieste, Italy

h Department of Urology, Kocaeli University School of Medicine, Kocaeli, Turkey

i Department of Urology, Kocaeli University School of Medicine, Kocaeli, Turkey

j Urology Clinic, Department of Urology, University of Trieste, Trieste, Italy

k Department of Urology, University Hospitals Leuven, Leuven, Belgium

l Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy

m Department of Urology, Pederzoli Hospital, Peschiera del Garda, Italy

n Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain

o Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy

p Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

*Corresponding authors. Department of Urology, SS Annunziata Hospital, G. D’Annunzio University of Chieti, Chieti, Italy (M. Marchioni). Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Largo Brambilla 3, 50134 Firenze, Italy. Tel. +39 055 275 8020; Fax: +39 055 275 8014 (R. Campi).

E-mail addresses: mic.marchioni@gmail.com (M. Marchioni) riccardo.campi@gmail.com (R. Campi).

October 4, 2022
Associate Editor: M. Carmen Mir